BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37875657)

  • 1. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Miller KA; Degan S; Wang Y; Cohen J; Ku SY; Goodrich DW; Gelman IH
    Oncogene; 2024 Jan; 43(1):22-34. PubMed ID: 37875657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Miller K; Degan S; Wang Y; Cohen J; Ku SY; Goodrich D; Gelman I
    Res Sq; 2023 May; ():. PubMed ID: 37292818
    [No Abstract]   [Full Text] [Related]  

  • 3. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.
    Lee SH; Poulogiannis G; Pyne S; Jia S; Zou L; Signoretti S; Loda M; Cantley LC; Roberts TM
    Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11002-7. PubMed ID: 20534477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
    Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
    Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
    Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
    Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
    Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.
    Bertacchini J; Mediani L; Beretti F; Guida M; Ghalali A; Brugnoli F; Bertagnolo V; Petricoin E; Poti F; Arioli J; Anselmi L; Bari A; McCubrey J; Martelli AM; Cocco L; Capitani S; Marmiroli S
    J Cell Physiol; 2019 Jul; 234(7):11188-11199. PubMed ID: 30565691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN-deficient cancers depend on PIK3CB.
    Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
    Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
    J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
    Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
    Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
    Fang J; Ding M; Yang L; Liu LZ; Jiang BH
    Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway.
    Kong L; Schäfer G; Bu H; Zhang Y; Zhang Y; Klocker H
    Carcinogenesis; 2012 Apr; 33(4):751-9. PubMed ID: 22301279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
    Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
    J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
    Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z
    Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
    Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
    Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
    Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
    Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas.
    Xie S; Ni J; McFaline-Figueroa JR; Wang Y; Bronson RT; Ligon KL; Wen PY; Roberts TM; Zhao JJ
    Cell Rep; 2020 Sep; 32(13):108196. PubMed ID: 32997991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.